August 5, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the company has been formally approved by the SEC for our S-1 and will now be a SEC reporting company. This is an important milestone as CTT Pharma is now an audited, SEC reporting company on the OTCQB and will start filing an SEC form 8-K when material events occur. CTT will update shareholders as more news becomes available.

 

About CTT Pharmaceutical Holdings, Inc.

CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company’s patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.

Forward-Looking Statements

Forward-looking statements include statements regarding the Company’s plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

CTT Pharmaceutical Holdings, Inc.

813-606-0060